Loading...
XKRX
006280
Market cap994mUSD
Apr 30, Last price  
124,200.00KRW
1D
0.57%
Jan 2017
-20.89%
Name

Green Cross Corp

Chart & Performance

D1W1MN
P/E
—
P/S
0.84
EPS
—
Div Yield, %
—
Shrs. gr., 5y
1.94%
Rev. gr., 5y
4.17%
Revenues
1.68t
+3.27%
442,299,046,000516,096,685,000643,208,349,000791,015,317,000767,911,770,550811,774,313,000888,168,207,110975,327,105,7301,047,812,247,3301,197,903,918,4001,287,916,286,2201,334,877,810,1101,369,709,726,8001,504,115,278,6501,537,825,750,2501,711,312,739,5301,626,643,815,8201,679,891,941,470
Net income
-26.28b
L-1.32%
44,357,145,00048,872,734,00080,524,433,000104,688,642,00055,367,168,00053,643,053,42070,066,278,51083,944,674,44094,967,401,93062,969,546,58053,246,604,74034,429,474,380-11,287,400,06081,048,858,100123,211,805,90065,453,133,850-26,631,783,140-26,280,215,150
CFO
-53.46b
L+876.83%
35,223,947,000-20,729,139,000112,006,156,00084,471,459,00054,855,488,03050,756,715,57029,689,475,48056,763,005,92045,243,777,660-1,742,284,53057,879,006,00014,410,216,14040,291,382,03035,973,500,910125,978,948,880119,154,310,880-5,472,809,765-53,460,079,250
Dividend
Dec 27, 20231500 KRW/sh
Earnings
Aug 04, 2025

Profile

Green Cross Corporation, a biopharmaceutical company, develops drugs and vaccines in South Korea. The company provides plasma derivatives, including albumin, immunoglobulin, and antithrombin; and vaccines for hepatitis-B, Hantavirus hemorrhagic fever, influenza, flu, and varicella. It also offers prescription drugs for the bleeding symptom control and hemostasis for persons with hemophilia A; prevention and treatment of bleeding episodes induced by hemophilia A and post-operative treatment; and treatment of neutropenia, hunter syndrome, and liver cancer, as well as treatment of anti-inflammation, pain relief, and osteoarthritis. In addition, the company provides over the counter drugs. It also exports its products to approximately 50 countries. The company has a licensing and collaboration agreement with Tottori University for development of GM1 gangliosidosis chaperone therapy. The company was formerly known as Sudo Microorganism Medical Supplies Company and changed its name to Green Cross Corporation in 1971. Green Cross Corporation was founded in 1967 and is headquartered in Yongin-si, South Korea. Green Cross Corporation is a subsidiary of Green Cross Holdings Corporation.
URL
http://gcbiopharma.com/
IPO date
Aug 01, 1989
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,679,891,941
3.27%
1,626,643,816
-4.95%
1,711,312,740
11.28%
Cost of revenue
1,494,273,594
1,449,900,646
1,485,926,073
Unusual Expense (Income)
NOPBT
185,618,347
176,743,170
225,386,666
NOPBT Margin
11.05%
10.87%
13.17%
Operating Taxes
1,527,336
(7,326,032)
16,313,075
Tax Rate
0.82%
7.24%
NOPAT
184,091,012
184,069,202
209,073,591
Net income
(26,280,215)
-1.32%
(26,631,783)
-140.69%
65,453,134
-46.88%
Dividends
(19,532,262)
(24,824,693)
(23,985,081)
Dividend yield
0.87%
1.73%
1.62%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
392,224,795
532,595,835
198,995,806
Long-term debt
546,632,909
312,297,668
485,877,823
Deferred revenue
14,570,000
15,884,214
22,693,024
Other long-term liabilities
38,834,822
25,010,374
17,558,438
Net debt
690,953,878
588,541,230
363,234,636
Cash flow
Cash from operating activities
(53,460,079)
(5,472,810)
119,154,311
CAPEX
(31,991,845)
(125,991,501)
(94,690,240)
Cash from investing activities
(67,894,170)
(150,243,304)
(205,259,307)
Cash from financing activities
93,845,335
100,511,823
(2,480,543)
FCF
56,669,644
39,216,405
226,773,439
Balance
Cash
23,995,031
55,506,128
112,305,916
Long term investments
223,908,796
200,846,144
209,333,077
Excess cash
163,909,229
175,020,082
236,073,357
Stockholders' equity
1,102,139,112
1,181,960,389
1,998,044,166
Invested Capital
1,970,282,793
2,129,759,976
1,924,774,520
ROIC
8.98%
9.08%
10.98%
ROCE
7.84%
7.66%
10.42%
EV
Common stock shares outstanding
12,564
11,413
11,413
Price
179,500.00
43.03%
125,500.00
-3.09%
129,500.00
-40.60%
Market cap
2,255,221,486
57.45%
1,432,353,839
-3.09%
1,478,006,551
-40.60%
EV
3,174,546,146
2,260,522,085
2,079,760,688
EBITDA
266,652,514
252,298,170
290,482,666
EV/EBITDA
11.91
8.96
7.16
Interest
40,439,237
28,483,187
18,392,691
Interest/NOPBT
21.79%
16.12%
8.16%